Figure 3

Cost distribution for management of adverse events with sunitinib and bevacizumab plus IFN in the United Kindgdom, Germany, France and Italy. ^aOn the basis of costs of managing grade 3–4 costs only; ^badverse events with proportional cost <5% are grouped. IFN=interferon-α2a; GI=gastrointestinal.